CDN 1163

Product Description

CDN 1163 is a SERCA2 allosteric activator. Increases Ca²⁺-ATPase activity and Ca²⁺ uptake by ER microsomes from obese mice. Rescues HEK cells from ER stress-induced cell death. Reduces fasting glucose levels and adipose tissue weight, and increases energy expenditure in ob/ob mice. Also improves glucose tolerance and reverses hepatic steatosis in ob/ob mice. Neuroprotective, improves memory and cognition in a mouse Alzheimer's disease model and reduces dyskinesia in rat model of Parkinson's disease. Orally bioavailable.

Solubility

Preparing Stock Solutions for CDN 1163

The following data is based on the product molecular weight 320.38

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.12 mL	15.61 mL	31.21 mL
5 mM	0.62 mL	3.12 mL	6.24 mL
10 mM	0.31 mL	1.56 mL	3.12 mL
50 mM	0.06 mL	0.31 mL	0.62 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Krajnak and Dahl A new target for Alzheimer's disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice. Bioorg.Med.Chem.Lett. 2018 PMID: 29602679
• Dahl A new target for Parkinson's disease: small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. Bioorg.Med.Chem.Lett. 2017 PMID: 27776889
• Kang Small molecular allosteric activator of the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) attenuates diabetes and metabolic disorders. J.Biol.Chem. 2016 PMID: 26702054